NRX Pharma Reports 2025 Results, Advances Ketamine Therapy Toward FDA Approval

NRX Pharmaceuticals (NASDAQ: NRXP) reported its full-year 2025 results, highlighting reduced operating expenses, growing revenue, and a cash position of approximately $7.8 million, supporting operations into 2026. The company continues to demonstrate financial discipline while advancing key programs in mental health treatment. NRX expects potential FDA approval of its preservative-free ketamine therapy in the second half of 2026 and is progressing development of NRX-100, targeting severe depression. The company is also expanding its Hope Therapeutics network, supporting its transition toward commercial growth and revenue generation. Tags #NRXPharmaceuticals #NRXP #Biotech #MentalHealth #KetamineTherapy #FDAApproval #DepressionTreatment #ClinicalTrials #HealthcareInnovation #BiotechInvesting #Neuroplasticity #Psychiatry #Pharmaceuticals #AnaBerry #NewsOut